CTMX

CytomX Therapeutics, Inc. (CTMX) | Rumor.io

CytomX Therapeutics

CTMX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,777

Bullish sentiment (50-day avg)79%

Price to earnings ratio15.9

Market capitalization586.1M

Earnings per share-0.57

Dividend yield (TTM)—

Revenue (annual)76.2M

Net income (annual)-17.4M

Social

What share of all stock conversation is about CTMX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 15

CTMX shares fell 10.63% on Tuesday, sliding from $3.20 to $2.86 in intraday trading, extending a pullback that began after a decline.
Analysts attribute the decline to market-maker/algo shorting and liquidity provision, with some genuine short exposure mixed in, but not a coordinated short attack.
The company's stock price has been subject to volatility, with some speculating that it may continue to decline, while others remain optimistic and advise patience.

Generated by AI

Sentiment

Of the messages about CTMX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	63.64% -36.36	81.82% +8.01	82.74% -5.26
Bearish	—	36.36% +36.36	18.18% -8.01	17.26% +5.26

Bullish· Mar 19

$CTMX has strong data supporting its Varseta asset, which has a large market opportunity and is considered better than current drugs in the class.
Analysts are highly bullish on $CTMX, with multiple firms raising their price targets, including HC Wainwright, Guggenheim, and Barclays, with some seeing a potential market value of $10 billion.
$CTMX has a favorable setup for further price increases, with a strong technical setup and a high likelihood of additional analyst upgrades.

Bearish· Mar 18

The management team of CytomX Therapeutics, Inc. is considered one of the worst around, contributing to the stock's decline.
The company's stock price has dropped significantly, down 18% after the underwriters placed offering shares, and may continue to fall due to excessive dilution.
The stock's recent performance, including a "pop and drop" pattern, suggests that it is likely to continue declining, with some predicting a price drop to $3-$3.5 or even below $4.

Generated by AI

Topics

Of the messages about CTMX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	70%	78.83%
Technical Analysis	—	100%	30%	12.83%
Analysts	—	0%	0%	5.75%
Controversies	—	0%	0%	0.12%
Earnings	—	0%	0%	2.47%
Macro	—	0%	0%	0%

Analysts· Mar 16

H.C. Wainwright raised the price target on CytomX Therapeutics to $17 from $10 and keeps a Buy rating, citing Phase 1 expansion data for varsetatug masetecan.
Oppenheimer upgraded CytomX Therapeutics to $12 from $10, reiterated at an Outperform rating, and says that data continues to support its view that CX-2051 could be a game-changer.
JPMorgan upgraded CytomX Therapeutics to Overweight from Neutral, citing the drug's good effectiveness and safety, and now expects up to $1.5B in U.S. peak sales.

Announcements· Mar 18

CytomX Therapeutics, Inc. has announced the pricing of a $250 million offering of common stock and pre-funded warrants, with 45.99 million shares issued at $5.30 per share.
The offering is expected to dilute existing shareholders, with 16.71 million outstanding stock options and 5.77 million tranche warrants potentially issued at lower prices.
CytomX's masked, T-cell engager technology has been terminated by Astellas, which has opted for a new partnership with Vir Bio instead, in a shift that may impact the future of the company's "Probody" era.

Technical Analysis· Mar 17

$CTMX has broken through resistance at $547.07 with strong volume, confirming a breakout, with a target of $1009.93 and a potential +44.23% increase.
The stock's momentum is fueled by a recent public offering, with traders advised to monitor the situation closely.
A technical analysis of the chart suggests a potential pullback to 161.8% before a possible impulsive move to 261.8% fib at $8.79.

Generated by AI

Community

Of the messages about CTMX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	85.71%	64.89%	64.84%
Newcomers	50%	14.29%	35.11%	35.16%

Regulars· Sep 15

The CTMX stock price dropped by 10.63% on Tuesday, with the decline extending a pullback that began after a prior close of $3.20.
Some regulars believe the decline is due to market-maker/algo shorting and liquidity provision, with some genuine short exposure mixed in, but not a coordinated short attack.
The stock price is expected to rebound, with some predicting a runup after the current decline, and others expecting a significant drop, with one target price being $1.77.

Newcomers· Mar 19

New traders are focusing on the price level of $4.50-$4.60, considering it a key area to watch for potential breaks.
Some newcomers are looking at the potential for a strike risk at $5, with a notable amount of open interest from March.
A few traders are observing the volume and chart patterns, noting a possible capitulation and testing of descending wedge support.

Generated by AI

News

CytomX at Morgan Stanley conference: late-line crc push gains focus

15d agoInvesting.com

CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow

19d agoSeeking Alpha

Also Discussed

Investors talking about CTMX also mention

#	Name	Attention
1	Xilio Therapeutics, Inc.XLO	0%0
2	Janux Therapeutics, Inc.JANX	0%0
3	BioAtla Inc.BCAB	0%new
4	TERN - Terns Pharmaceuticals, Inc.	——
5	LVTX - LAVA Therapeutics N.V.	——
6	Neo-Concept International Group Holdings Limited Class A Ordinary SharesNCI	0.01%+0.01
7	Cullinan Therapeutics Inc.CGEM	0%new
8	MKDWELL Tech Inc.MKDW	0%+0
9	LanzaTech Global Inc. Common StockLNZA	0%new
10	Distribution Solutions Group, Inc.DSGR	0%0

CytomX Therapeutics, Inc.

Healthcare
Biotechnology

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company develops conditionally activated biologics through its Probody therapeutic platform, with the goal of localizing activity to the tumor microenvironment and limiting effects on healthy tissue. Its current pipeline spans multiple cancer-focused modalities, including antibody-drug conjugates, T-cell engagers, and immune-modulating therapies such as cytokines. CytomX Therapeutics also advances programs aimed at difficult-to-treat tumors, supporting research and development across a range of solid-tumor indications. Headquartered in South San Francisco, California, CytomX Therapeutics plays a specialized role in the biotechnology market as a developer of targeted cancer therapeutics designed for precision and selectivity.

Website

Location

151 Oyster Point Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about CTMX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 15

CTMX shares fell 10.63% on Tuesday, sliding from $3.20 to $2.86 in intraday trading, extending a pullback that began after a decline.
Analysts attribute the decline to market-maker/algo shorting and liquidity provision, with some genuine short exposure mixed in, but not a coordinated short attack.
The company's stock price has been subject to volatility, with some speculating that it may continue to decline, while others remain optimistic and advise patience.

Generated by AI

Sentiment

Of the messages about CTMX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	63.64% -36.36	81.82% +8.01	82.74% -5.26
Bearish	—	36.36% +36.36	18.18% -8.01	17.26% +5.26

Bullish· Mar 19

$CTMX has strong data supporting its Varseta asset, which has a large market opportunity and is considered better than current drugs in the class.
Analysts are highly bullish on $CTMX, with multiple firms raising their price targets, including HC Wainwright, Guggenheim, and Barclays, with some seeing a potential market value of $10 billion.
$CTMX has a favorable setup for further price increases, with a strong technical setup and a high likelihood of additional analyst upgrades.

Bearish· Mar 18

The management team of CytomX Therapeutics, Inc. is considered one of the worst around, contributing to the stock's decline.
The company's stock price has dropped significantly, down 18% after the underwriters placed offering shares, and may continue to fall due to excessive dilution.
The stock's recent performance, including a "pop and drop" pattern, suggests that it is likely to continue declining, with some predicting a price drop to $3-$3.5 or even below $4.

Generated by AI

Topics

Of the messages about CTMX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	70%	78.83%
Technical Analysis	—	100%	30%	12.83%
Analysts	—	0%	0%	5.75%
Controversies	—	0%	0%	0.12%
Earnings	—	0%	0%	2.47%
Macro	—	0%	0%	0%

Analysts· Mar 16

H.C. Wainwright raised the price target on CytomX Therapeutics to $17 from $10 and keeps a Buy rating, citing Phase 1 expansion data for varsetatug masetecan.
Oppenheimer upgraded CytomX Therapeutics to $12 from $10, reiterated at an Outperform rating, and says that data continues to support its view that CX-2051 could be a game-changer.
JPMorgan upgraded CytomX Therapeutics to Overweight from Neutral, citing the drug's good effectiveness and safety, and now expects up to $1.5B in U.S. peak sales.

Announcements· Mar 18

CytomX Therapeutics, Inc. has announced the pricing of a $250 million offering of common stock and pre-funded warrants, with 45.99 million shares issued at $5.30 per share.
The offering is expected to dilute existing shareholders, with 16.71 million outstanding stock options and 5.77 million tranche warrants potentially issued at lower prices.
CytomX's masked, T-cell engager technology has been terminated by Astellas, which has opted for a new partnership with Vir Bio instead, in a shift that may impact the future of the company's "Probody" era.

Technical Analysis· Mar 17

$CTMX has broken through resistance at $547.07 with strong volume, confirming a breakout, with a target of $1009.93 and a potential +44.23% increase.
The stock's momentum is fueled by a recent public offering, with traders advised to monitor the situation closely.
A technical analysis of the chart suggests a potential pullback to 161.8% before a possible impulsive move to 261.8% fib at $8.79.

Generated by AI

Community

Of the messages about CTMX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	85.71%	64.89%	64.84%
Newcomers	50%	14.29%	35.11%	35.16%

Regulars· Sep 15

The CTMX stock price dropped by 10.63% on Tuesday, with the decline extending a pullback that began after a prior close of $3.20.
Some regulars believe the decline is due to market-maker/algo shorting and liquidity provision, with some genuine short exposure mixed in, but not a coordinated short attack.
The stock price is expected to rebound, with some predicting a runup after the current decline, and others expecting a significant drop, with one target price being $1.77.

Newcomers· Mar 19

New traders are focusing on the price level of $4.50-$4.60, considering it a key area to watch for potential breaks.
Some newcomers are looking at the potential for a strike risk at $5, with a notable amount of open interest from March.
A few traders are observing the volume and chart patterns, noting a possible capitulation and testing of descending wedge support.

Generated by AI

CytomX Therapeutics

Social

Sep 15

Bullish· Mar 19

Bearish· Mar 18

Analysts· Mar 16

Announcements· Mar 18

Technical Analysis· Mar 17

Regulars· Sep 15

Newcomers· Mar 19

CytomX at Morgan Stanley conference: late-line crc push gains focus

CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow

CytomX at cantor healthcare conference: pipeline gains, safety test ahead

CytomX at Wells Fargo conference: epcam bet and cash strength

CytomX Therapeutics to Present at Upcoming September Investor Conferences

FDA grants fast track status to CytomX’s colorectal cancer drug

Also Discussed

CytomX Therapeutics, Inc.

Company Information

Location

CytomX at Morgan Stanley conference: late-line crc push gains focus

CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow

CytomX at cantor healthcare conference: pipeline gains, safety test ahead

CytomX at Wells Fargo conference: epcam bet and cash strength

CytomX Therapeutics to Present at Upcoming September Investor Conferences

FDA grants fast track status to CytomX’s colorectal cancer drug

Also Discussed

Social

Sep 15

Bullish· Mar 19

Bearish· Mar 18

Analysts· Mar 16

Announcements· Mar 18

Technical Analysis· Mar 17

Regulars· Sep 15

Newcomers· Mar 19